| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.065 | 0.04 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.04 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.05 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.05 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.062 | 0.05 |